Overview

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

Status:
Recruiting

Trial end date:
2020-10-31

Target enrollment:

Participant gender:

Summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Prolia® in healthy adults

Phase:

Phase 1

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

Denosumab